Treats active duodenal ulcer. ANDA 202396, held by Mylan. Lansoprazole.
As of Nov 21, 2026, ANDA 202396 (Lansoprazole), held by Mylan, was first approved by FDA on Nov 28, 2018, with 4 approved supplements and 0 published complete response letters.
Lansoprazole delayed-release orally disintegrating tablets are a proton pump inhibitor (PPI) indicated for the:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 28, 2018 | Original application | Approved | None posted |
| Lansoprazole15MG · tablet, orally disintegrating, delayed release;oral | Lansoprazole | Rx |
| Lansoprazole30MG · tablet, orally disintegrating, delayed release;oral | Lansoprazole | Rx |
| May 3, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 3, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 3, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 12, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 28, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters